Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, Geoffrey Chong, Edward Yoo, Chan Y Cheah, Nunzio Franco, Bianca Nguyen, Howard Mutsando, Fatima Tahir, Judith Trotman, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M Johnston, Michael Dickinson, Stephen Opat, Zoe K McQuilten, Erica M Wood, Gayathri St George, Eliza A Hawkes
Follicular Lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d'Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision-making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced stage rituximab-era FL...
March 7, 2024: Haematologica